China said Monday it would begin regulating all fentanyl-related drugs as a class of controlled substances, in a change US officials had long advocated as a way to stem the flow of lethal opioids from China.
The sweeping change in the way China regulates drugs that mimic fentanyl takes effect May 1 and could help end the game of regulatory whack-a-mole with chemists who can manufacture novel opioids faster than they can be banned.
It could also facilitate prosecutions of opioid merchants in China, who until now have skirted the law by manufacturing and exporting fentanyl variants that were technically legal in China.
"We firmly believe that listing the entire class of fentanyl substances will completely block the loopholes that enable law breakers to evade punishment by simply modifying one or several atoms, functional groups or other groups," said Liu Yuejin, vice-commissioner of China's National Narcotics Control Commission.
"It will effectively prevent the massive abuse of fentanyl substances and illegal drug trafficking and smuggling activities, and contribute to global drug control with China's wisdom and power."
"It cannot be the main source for the United States. The US accusation lacks evidence and is contrary to the facts."
"The two sides are still progressing with cooperative investigative work. The US, however, now takes some measures like indictments without informing us beforehand. This undermines the sound atmosphere of two sides' cooperation. We express regret for this."
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
